retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% The most intensive medical obesity

Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes

Prioritize protein at every meal This is the single most impactful dietary change

Wang, C

Visible body-composition changes usually develop over 812+ weeks when paired with nutrition, movement, and sleep optimization

Frequently asked questions How often do you inject retatrutide

The pre-specified primary efficacy analyses included data from study 1 and pooled data from studies 2 and 3, regardless of glycemic rescue or treatment discontinuation